ALLURION TECHNOLOGIES, INC. Understanding Allurion's NYSE Delisting and What It Means for Investors

Let's dive into the latest significant development for Allurion Technologies, Inc. This summary aims to explain the recent SEC filing clearly, whether you're a seasoned investor or just getting started.

---

Event Description (what happened)

Allurion Technologies, Inc. recently announced a significant development: the New York Stock Exchange (NYSE) began the process to delist Allurion's common stock and warrants. Consequently, the NYSE suspended trading of Allurion's shares, which now trade on the OTCID Market, a less regulated platform.

The NYSE made this decision because Allurion failed to meet a key listing requirement: its average market capitalization (the total value of its outstanding shares) dropped below $15 million for 30 consecutive trading days. Allurion is appealing this decision, but for now, its stock no longer trades on the "big board."

Companies listed on major exchanges like the NYSE must meet ongoing requirements, and minimum market capitalization is a critical one. Allurion's market cap dipped below the NYSE's $15 million threshold for too long, triggering the delisting process. This low market value reflects a significant decline in investor confidence, likely indicating underlying financial challenges such as insufficient revenue growth, ongoing operating losses, or a need for additional capital.

Notably, this news follows Allurion's recent FDA approval for its Allurion Gastric Balloon System (featuring the Allurion Smart Capsule) in the U.S. The company announced this approval in September 2023, marking a major positive milestone. Allurion developed a detailed plan to leverage this approval, aiming to boost its business, strengthen its financial position, and potentially regain compliance with NYSE rules or relist on another exchange like NYSE American. This plan, shared with the NYSE, focuses on:

• Accelerating the U.S. commercial launch of the Allurion Gastric Balloon System to drive significant revenue growth.
• Improving operational efficiency and managing costs to reduce its cash burn.
• Exploring strategic financing options to strengthen its balance sheet and fund U.S. expansion.

Allurion is actively executing this strategy even as the delisting process unfolds.

Event Date/Timeline

The NYSE officially notified Allurion and suspended trading on March 6, 2026, after market close. Allurion then issued a press release on March 12, 2026, confirming the news and its plan to appeal. For context, the FDA approved their system in September 2023.

Impact Assessment (who/what is affected)

Being delisted from a major exchange like the NYSE is a significant event, as the company's stock now trades on the OTCID Market. This market is generally less visible, has fewer trading rules, and can make it significantly harder for investors to buy and sell shares.

The move to OTCID often leads to several consequences:

• Lower trading volume and liquidity: Fewer buyers and sellers can make it difficult to execute trades quickly or at desired prices.
• Increased price volatility: Lower liquidity can cause larger price swings.
• Reduced institutional investor interest: Many institutional funds have mandates preventing investment in OTC-traded securities, which limits the pool of potential investors.
• Perception of instability: Delisting can make a company appear less stable, potentially hindering its ability to raise capital or attract new investors on favorable terms.

Who does this impact?

• Investors: If you own Allurion stock or warrants, your investment now trades on a less liquid market, potentially making it harder to sell shares quickly or at a good price. The stock price could also become more volatile.
• Allurion Employees: While the company states this does not immediately affect its business operations, a delisting can impact employee morale, the value of stock options, and the company's ability to attract top talent.
• Customers: The company states its business operations are unaffected, so customers should continue to receive the same product and support. However, long-term financial instability could eventually impact product development or availability.
• Management: Management will focus on appealing the delisting and implementing their strategic plan. This process presents a significant distraction and a major challenge, consuming valuable resources.
• Competitors: Competitors will closely watch how this affects Allurion's market position and might adjust their strategies, potentially viewing Allurion's struggles as a weakness.

What's next?

• Immediate: The stock already trades on the OTCID Market under its current symbols "ALUR" and "ALUR.WS." The company intends to apply for listing on a "higher-tier" OTC market (like OTCQB or OTCQX), which might offer more visibility and stricter reporting requirements, though it remains distinct from a major exchange.
• Short-term: Allurion's appeal process will unfold. If the appeal fails, the NYSE will file a Form 25 with the SEC, and the delisting will become final 10 days later. Meanwhile, the company will diligently execute its strategic plan to strengthen its balance sheet and aggressively commercialize its FDA-approved product in the U.S. This includes actively seeking capital to fund growth initiatives.
• Long-term: The key question is whether Allurion can successfully execute its plan to improve its financial standing, achieve significant revenue growth from the U.S. launch, and either relist on a major exchange (like NYSE or NYSE American) or thrive on the OTC market. Its ability to secure adequate funding for the U.S. launch and demonstrate a clear path to profitability will be crucial for long-term success and for attracting renewed investor interest.

Financial Impact (if applicable)

The primary financial event leading to the delisting is the company's average market capitalization falling below the NYSE's $15 million threshold for 30 consecutive trading days. This indicates underlying financial challenges, such as insufficient revenue growth, ongoing operating losses, or a need for additional capital.

The delisting itself carries significant financial implications:

• Higher cost of capital: If Allurion needs to raise capital, it may face higher interest rates or have to issue shares at a greater discount due to the increased risk perception associated with an OTC listing.
• Difficulty in raising capital: Reduced institutional investor interest and a perception of instability can make it harder to attract new investors or secure financing on favorable terms.
• Potential for dilution: If the company raises capital, it might do so at lower valuations, leading to greater dilution for existing shareholders.
• Focus on financial improvement: The company's strategic plan explicitly aims to strengthen its financial position by accelerating U.S. commercial launch to drive revenue, improving operational efficiency to reduce its cash burn, and exploring strategic financing options to fund its expansion. Investors should pay close attention to Allurion's cash position, cash burn rate, revenue growth from the U.S. launch, and any announcements regarding capital raising efforts, as the ability to fund operations and growth is paramount.

Key Takeaways for Investors

For investors and casual followers, here are the key takeaways:

• Volatility Alert: Expect increased stock price volatility in the short term, especially with trading on the less liquid OTCID Market.
• Do Your Homework: Don't just react to headlines. Read the company's official press release and the SEC filing (Form 8-K) for accurate information. Critically assess its strategic plan and look for concrete milestones.
• Understand the Financials: The delisting signals underlying financial challenges. Investors should pay close attention to Allurion's cash position, cash burn rate, revenue growth from the U.S. launch, and any announcements regarding capital raising efforts. The ability to fund operations and growth is paramount.
• Consider the "Why": Understand why this happened (the market cap rule, indicating financial distress) and what it means for the company's core business. Is the FDA approval and U.S. launch enough to turn things around, or is the financial situation too dire to overcome the challenges of an OTC listing?
• Long vs. Short: Trading on the OTCID Market is generally riskier and less liquid than on a major exchange. Longer-term investors should assess how this delisting changes the company's overall value and future prospects, particularly its ability to raise capital, grow revenue, and achieve profitability. Be aware of the increased risk of dilution if the company raises capital at lower valuations.
• Don't Panic (or Get Overly Excited): Significant news can evoke strong emotions. Strive to remain rational and base decisions on facts and your investment strategy, not just hype or fear. The delisting is a serious event that significantly increases investment risk.

Keep a close eye on Allurion's next announcements, especially regarding its appeal, progress on strengthening its balance sheet, securing financing, and the actual financial results and commercialization milestones from its U.S. product launch. This is just one piece of the puzzle, but a very significant one for your investment decision.